Get the latest news alerts: at Twitter.

Local Tech Wire

RESEARCH TRIANGLE PARK, .N.C – Amber Salzman, former senior vice president of operations for medicines development at GlaxoSmithKline (NYSE: GSK), is the new chief executive officer at

The privately held firm is based in Philadelphia.

Salzman also will be a member of the Cardiokine board. She has 25 years of experience in the pharmaceutical industry, including a lead role in establishing GSK’s development support center in India.

“Amber’s record of accomplishment and her passion to develop new medications for patients in need make her particularly well suited to lead Cardiokine during this next promising period in the company’s history,” said James Cavanaugh, the chair of the Cardiokine board.

Cardiokine, which has had three CEOs over the past three years according to the Philadelphia Business Journal, has a drug candidate in Phase III clinical trials targeting cardiovascular disease. It is partnering with Biogen in developing the compound called Lixivaptan.

GSK employs some 4,000 people in the RTP region where it maintains its U.S. headquarters.